Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody ... Abpro CorporationDecember 16, 2020 GMT ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studies safety, tolerability, efficacy, and pharmacokinetics of ABP300 in approximately 2,000 subjects WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the initiation of global Phase 2/3 registrational studies evalu...
Source: apnews.com